Citation Impact
Citing Papers
Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
2014
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2016
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
2011
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
2011
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
2011
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
2013
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Breast cancer
2019 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
2011
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
2012
Gastric cancer
2016 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
2012
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
2013 Standout
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
QuPath: Open source software for digital pathology image analysis
2017 Standout
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Breast cancer
2016 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Translating cancer research into targeted therapeutics
2010 Nature
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
2012
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
2007
An International Ki67 Reproducibility Study
2013
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
2010
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
2009
Tumour heterogeneity in the clinic
2013 Nature
The molecular biology of head and neck cancer
2010 Standout
Significance of immunohistochemistry in breast cancer
2014
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer
2011
Antibody therapy of cancer
2012 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
The cancer biomarker problem
2008 Nature
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
2012
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Deep learning in histopathology: the path to the clinic
2021 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Risk of early recurrence among postmenopausal women with estrogen receptor‐positive early breast cancer treated with adjuvant tamoxifen
2008
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
2012 Standout
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Digital pathology and artificial intelligence
2019 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Biological determinants of endocrine resistance in breast cancer
2009
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
2018
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
2008
Breast Cancer–Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment
2020
Identifying and assessing women at high risk for breast cancer
2009
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
Preoperative chemotherapy for women with operable breast cancer
2007
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
2007
Breast Cancer Treatment
2019 Standout
Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
2009
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
2009
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2015
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
A New Initiative on Precision Medicine
2015 Standout
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
2008
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
2011
How to treat male breast cancer
2007
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Primary Systemic Therapy of Breast Cancer
2006
Works of Anthony Skene being referenced
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
2010
Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer
2015
Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
2008
Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer
2007
Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial
2005
Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival
2005
Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists
2005
Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
2006
A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer
2007